In China &
Link Health Group was established in 2012. Since its establishment, our team has participated in more than 30 License cases and gained solid experience in licensing commercial, registration and clinical development. Since 2020, Link health Group created two major business: Link Consulting, to provide professional service on licensing and clinical development, and Link Pharma, to do R&D in innovative drugs and drug-device combo products to for the therapy on dental and Orthopedic .disease.
Dr. Yan Song (CEO)
Twente University, Netherlands. Dr Song worked in Germany and Netherlands as a scientist and entered the CRO field in 2010. After 2012, she founded Link Health and completed more than 10 licensing deals. As a well-known expert for licensing in China, she has sponsored and supervised a number of partnership deals for some of the worlds leading biotech companies. Among these deals, she has supported and completed 8 INDs and 2 NDAs in China and A/P. In 2020, she finalized a JV partnership with a well-know global CRO company George Clinical in China, creating important service elements for ¡°Link Consulting¡± Dr Song is also the founder for Link Pharma, which is a biotech company dedicated to the global research and development of innovative orthopedic medicinal products.
Zhenfei Yin (General Manager)
Zhenfei Yin has over 15 years of substantial industry experience, leading in roles such as Clinical Operations, Project Management, and Business Development in teams across the CRO and Pharmaceutical sectors, Prior to Link, Zhenfei acted as PM director (Great China) of ICON, PM & BD director of WuXi CDS (former WuXi PRA), and Head of BD, PM and strategy solution in IQVIA (KunTuo). He successfully managed a team of 120+ conducting clinical trials across phase 1-4, covering different therapeutic areas, including oncology, CV, CNS, Infectious disease, respiration and the medical device/IVD area. Zhenfei obtained his degree in Clinical Medicine from Shanxi Medical University and also holds a Master¡¯s Degree in Surgery from Peking University First Hospital.
Yuansheng Xu (Vice President)
Dr. Xu has a PhD in pharmacology from Chinese Academy of Sciences and has worked in Guangzhou Institute of Scientific Research, Bio-Thera and other companies. He joined Link Health in 2014 and is mainly responsible for the preclinical pharmacological and toxicological research of innovative drugs, and has participated in the preclinical development of four new class 1 drugs of the company, and has rich experience in the development of innovative drugs, especially orthopedic and oncology drugs. At the same time, he has presided over and participated in scientific research projects such as China Postdoctoral Fund, Guangzhou Science and Technology Plan Project, National Natural Science Foundation of China, and applied for more than 30 patents.
CaiMei Wu (Vice President)
CaiMei has Over 20 years¡¯ experience in new drug registration. Prior to Link consult, she served as Director of Registration Affairs and Deputy General Manager in a global CRO company, where she was responsible for registration and international multi-center clinical trials, participated in the research and development site, and managed the production site verification of many projects. She has successfully filed over 30 INDs and NDA for 10 drugs. She is familiar with NMPA and FDA regulations and participated in China-US dual submissions.
Shiqun Zhang (R&D Director)
Dr. Zhang graduated from China Medical University with a PhD in pharmacology. He is in charge of the project and pre-clinical work of innovative drugs in HEC Pharml and Hong Kong Bright Future Pharmaceutical; he joined Link Health in November 2016 and is in charge of project research and clinical related work. He is one of the core members of the innovation team introduced by Guangdong Province, and has been awarded the certificate of Dongguan Characteristic Talent (Category II), and has completed 4 INDs of innovative drug projects as the main person in charge.
James Cheong (Board Member)
James Cheong is Chief Executive Officer of George Clinical. James has a wealth of business leadership experience and has more than 20 years of industry experience in both global pharma and CRO companies in the areas of Clinical Operations, Regulatory Affairs, Data Science and Regional Management. Prior to George Clinical, Cheong served as Head of Clinical Operations for the Chinese Market at Boehringer Ingelheim. Prior to this, Cheong acted as VP of Clinical Development at EPS International in the Asia-Pacific region, Senior Director for Clinical Operations at Parexel, and Director of Clinical Operations at ICON. Based in our Singapore office, James leads global operations and directs the company¡¯s administrative functions.